Olr184 inhibitors represent a unique and focused class of chemical compounds specifically designed to interfere with the activity of the Olr184 protein, a member of the olfactory receptor (OR) family. Olfactory receptors are G-protein-coupled receptors (GPCRs) that are predominantly expressed in the sensory neurons of the olfactory epithelium, where they are responsible for the detection of odorant molecules. The Olr184 protein is one of the numerous olfactory receptors identified in various organisms, and it plays a specialized role in the olfactory signaling pathway. Inhibitors targeting Olr184 are designed to modulate this specific receptor's activity, thereby affecting the signaling cascade it initiates upon interaction with its natural ligands. These inhibitors are typically small molecules that can bind to the Olr184 receptor, altering its conformational state, and consequently impeding its ability to interact with G-proteins or other intracellular signaling partners.
The design and synthesis of Olr184 inhibitors often involve detailed computational modeling to predict the binding interactions between the inhibitor molecules and the Olr184 receptor. This is typically followed by chemical synthesis and structural optimization to enhance the binding affinity and specificity of the inhibitors towards Olr184. These compounds are then characterized using a variety of techniques, including in vitro assays that measure the receptor's activity in the presence of the inhibitors. By studying the binding kinetics and the structural conformation of these inhibitors when bound to Olr184, researchers can gain insights into the molecular mechanisms governing olfactory receptor function and the broader implications for the olfactory signaling pathway. The specificity of these inhibitors also allows for precise modulation of olfactory receptor activity, making them valuable tools in the study of sensory biology and the underlying biochemical processes that contribute to olfaction.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
KPT 330 | 1393477-72-9 | sc-489062 | 5 mg | $173.00 | ||
XPO1 inhibitor, could impact nuclear export mechanisms potentially relevant to Olr184. | ||||||
BAY 80-6946 | 1032568-63-0 | sc-503264 | 5 mg | $562.00 | ||
PI3K inhibitor, may disrupt cell survival and growth pathways relevant to Olr184. | ||||||
Niraparib | 1038915-60-4 | sc-507492 | 10 mg | $150.00 | ||
PARP inhibitor, potentially affects DNA repair pathways linked to Olr184. | ||||||
CAL-101 | 870281-82-6 | sc-364453 | 10 mg | $193.00 | 4 | |
PI3K inhibitor, could modulate signaling pathways potentially involving Olr184. | ||||||
Filgotinib | 1206161-97-8 | sc-507393 | 10 mg | $150.00 | ||
JAK inhibitor, might alter cytokine signaling pathways affecting Olr184's function. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
CDK4/6 inhibitor, potentially impacts cell cycle regulation pathways related to Olr184. | ||||||
MEK 162 | 606143-89-9 | sc-488879 | 10 mg | $306.00 | ||
MEK inhibitor, could affect the MAPK/ERK pathway potentially linked to Olr184. | ||||||
Mocetinostat | 726169-73-9 | sc-364539 sc-364539B sc-364539A | 5 mg 10 mg 50 mg | $214.00 $247.00 $1463.00 | 2 | |
HDAC inhibitor, could alter chromatin structure and gene expression affecting Olr184. | ||||||
Acalabrutinib | 1420477-60-6 | sc-507392 | 250 mg | $255.00 | ||
Bruton's tyrosine kinase inhibitor, may modulate cell signaling pathways relevant to Olr184. | ||||||